<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41734">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01734824</url>
  </required_header>
  <id_info>
    <org_study_id>Vinforce-012</org_study_id>
    <secondary_id>Bone marrow edema</secondary_id>
    <nct_id>NCT01734824</nct_id>
  </id_info>
  <brief_title>Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo</brief_title>
  <official_title>Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <authority>Austria: Ethikkommission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The etiology of bone marrow edema (BME) is still uncertain. Several studies report
      therapeutic success with antiresorptive drugs.

      This study investigates antiresorptive and osteoanabolic drugs versus placebo in BME
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are assigned to receive either denosumab 60mg sc (once) or placebo or daily
      teriparatide sc for three months or placebo.

      MRI examinations at baseline and after three months will be performed. Serum bone turnover
      markers will be evaluated as well as QoL questionnaires.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Reduction/termination of bone marrow edema with antiresorptive and osteoanabolic drugs</measure>
    <time_frame>baseline - month 1 -  month 3</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>MRI examination, fasting serum levels of bone turnover markers, QoL-questionnaire, VAS score</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Bone Marrow Oedema Syndrome</condition>
  <condition>High Turnover Bone Disease</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Teriparatide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>daily subcutaneous injection of teriparatide 20Âµg for three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Teriparatide</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>daily subcutaneous teriparatide placebo injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Denosumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one subcutaneous injection of denosumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Denosumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one subcutaneous injection of denosumab placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>sc RANKL-inhibitor</description>
    <arm_group_label>Denosumab</arm_group_label>
    <other_name>Prolia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide</intervention_name>
    <description>daily subcutaneous injection of teriparatide</description>
    <arm_group_label>Teriparatide</arm_group_label>
    <other_name>PTH 1-34</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Denosumab</intervention_name>
    <description>one subcutaneous injection denosumab placebo</description>
    <arm_group_label>Placebo Denosumab</arm_group_label>
    <other_name>Prolia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Teriparatide</intervention_name>
    <description>daily subcutaneous placebo injection</description>
    <arm_group_label>Placebo Teriparatide</arm_group_label>
    <other_name>PTH 1-34</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MRI diagnosed bone marrow edema

        Exclusion Criteria:

          -  any prior antiresorptive or osteoanabolic treatment

          -  any prior therapy with strontium ranelate

          -  Hyper-/hypocalcemia

          -  malignancies

          -  pregnancy

          -  and contraindication against denosumab or teriparatide
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Muschitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University Vienna - St. Vincent Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>1060</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.vinforce.at</url>
    <description>non-profit web page</description>
  </link>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 27, 2013</lastchanged_date>
  <firstreceived_date>June 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Dr. Christian Muschitz</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>bone marrow edema, denosumab, PTH 1-84</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
